Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs

Author： Garg Vishvas  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.3, 2013-05, pp. : 299-307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Influence of Primary Care Prescribing Rates for New Drugs on Spontaneous Reporting of Adverse Drug Reactions

By Clark Richard C.  

Drug Safety, Vol. 30, Iss. 4, 2007-01 ,pp. : 357-366

Adis International

Access to resources Recommend Favorite

Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study

By Gavaza Paul  

Pharmacy World and Science, Vol. 32, Iss. 5, 2010-10 ,pp. : 651-657

Springer Publishing Company

Access to resources Recommend Favorite

Under-Reporting of Adverse Drug Reactions: A Systematic Review

By Hazell Lorna   Shakir Saad A.W.  

Drug Safety, Vol. 29, Iss. 5, 2006-01 ,pp. : 385-396

Adis International

Access to resources Recommend Favorite

Patients’ role in reporting adverse drug reactions

By van Grootheest Kees   de Jong-van den Berg Lolkje  

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 363-368

Informa Healthcare

Access to resources Recommend Favorite

Attitudes to reporting adverse drug reactions in northern Sweden

By Bäckström Martin   Mjörndal Tom   Dahlqvist Rune   Nordkvist-Olsson Torborg  

European Journal of Clinical Pharmacology, Vol. 56, Iss. 9-10, 2000-12 ,pp. : 729-732

Springer Publishing Company

Access to resources Recommend Favorite